Grant: Project Grant
University of Toronto
$100,000.00
Combining in vivo and in silico screening to identify new classes of anthelmintics targeting rhodoquinone-dependent metabolism
FY 2022-23
Summary
Soil-transmitted helminths (STHs) like hookworms are human parasites. They infect over a billion people causing malnutrition and death, with the greatest effects on children. Drugs for treating STH infections exist but there are few such drugs and resistance to these is growing. It is urgent that we develop new drugs to treat these major human infections. Our goal here is to find such new drugs.
The key problem is to find a drug that kills the parasite while leaving the human host untouched. We have to exploit the differences between host and parasite to do this. One key difference between humans and parasites is how they make energy. Humans breathe oxygen and this is how we burn our food to make energy. STHs often live in the human gut - there is little available oxygen and they adapted to use an unusual way to make energy. This relies on a small molecule called rhodoquinone (RQ) - without it they cannot survive. The beauty of RQ is that it is only made by the parasites - if we could stop the parasite making RQ, we could kill the worm without affecting its host. RQ is a perfect target.
We showed the nematode worm C.elegans makes RQ and we figured out how it makes RQ and the genes involved. We set up a simple way to test for new drugs that block its ability to make RQ and screened over 50,000 compounds to look for inhibitors. We now want to scale this up to screen 100,000 compounds for new blockers. We also found some key parasite proteins are subtly changed so they are different to their host counterparts. We used computers to predict drugs that may block the STH and not the host protein and we will test these predicted drugs in C.elegans. By combining large screens of compounds in the worm and predictions in computers we will find possible drugs. To confirm they truly kill parasites, we test these new drugs to see if they can kill parasites in a mouse. This should lead to new drugs that specifically target parasites by blocking key steps in their metabolism.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
477286
Name
Fraser Andrew G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Genomics: Systems and computational biology
Projecttitle
Combining in vivo and in silico screening to identify new classes of anthelmintics targeting rhodoquinone-dependent metabolism
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
C.Elegans Model; Drug Discovery; Helminth; High Throughput Phenotyping; Metabolic Networks; Quantitative Phenotyping; Rhodoquinone
Abstract
Soil-transmitted helminths (STHs) like hookworms are human parasites. They infect over a billion people causing malnutrition and death, with the greatest effects on children. Drugs for treating STH infections exist but there are few such drugs and resistance to these is growing. It is urgent that we develop new drugs to treat these major human infections. Our goal here is to find such new drugs.
The key problem is to find a drug that kills the parasite while leaving the human host untouched. We have to exploit the differences between host and parasite to do this. One key difference between humans and parasites is how they make energy. Humans breathe oxygen and this is how we burn our food to make energy. STHs often live in the human gut - there is little available oxygen and they adapted to use an unusual way to make energy. This relies on a small molecule called rhodoquinone (RQ) - without it they cannot survive. The beauty of RQ is that it is only made by the parasites - if we could stop the parasite making RQ, we could kill the worm without affecting its host. RQ is a perfect target.
We showed the nematode worm C.elegans makes RQ and we figured out how it makes RQ and the genes involved. We set up a simple way to test for new drugs that block its ability to make RQ and screened over 50,000 compounds to look for inhibitors. We now want to scale this up to screen 100,000 compounds for new blockers. We also found some key parasite proteins are subtly changed so they are different to their host counterparts. We used computers to predict drugs that may block the STH and not the host protein and we will test these predicted drugs in C.elegans. By combining large screens of compounds in the worm and predictions in computers we will find possible drugs. To confirm they truly kill parasites, we test these new drugs to see if they can kill parasites in a mouse. This should lead to new drugs that specifically target parasites by blocking key steps in their metabolism.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fraser, Andrew G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~